help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Published ahead of print on April 14, 2005, doi:10.1164/rccm.200409-1200OC
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Online Supplement
Right arrow All Versions of this Article:
200409-1200OCv1
171/12/1430    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Verver, S.
Right arrow Articles by van Helden, P. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Verver, S.
Right arrow Articles by van Helden, P. D.
American Journal of Respiratory and Critical Care Medicine Vol 171. pp. 1430-1435, (2005)
© 2005 American Thoracic Society
doi: 10.1164/rccm.200409-1200OC


Original Article

Rate of Reinfection Tuberculosis after Successful Treatment Is Higher than Rate of New Tuberculosis

Suzanne Verver, Robin M. Warren, Nulda Beyers, Madalene Richardson{dagger}, Gian D. van der Spuy, Martien W. Borgdorff, Donald A. Enarson, Marcel A. Behr and Paul D. van Helden

Desmond Tutu TB Center, Department of Pediatrics and Child Health, and MRC Center for Molecular and Cellular Biology, Department of Medical Biochemistry, Stellenbosch University, Cape Town, South Africa; KNCV Tuberculosis Foundation, The Hague; Department of Infectious Diseases, Tropical Medicine and AIDS, Academic Medical Center, Amsterdam, The Netherlands; International Union against Tuberculosis and Lung Disease (IUATLD), Paris, France; and Division of Infectious Diseases, Department of Medicine, McGill University Health Center, Montreal, Quebec, Canada

Correspondence and requests for reprints should be addressed to Suzanne Verver, M.Sc., Ph.D., KNCV Tuberculosis Foundation, P.O. Box 146, 2501 CC The Hague, The Netherlands. E-mail: ververs{at}kncvtbc.nl

Rationale: In a high–tuberculosis (TB) incidence area of Cape Town, South Africa, there is a very high rate of unexplained recurrent TB. The incidence of new bacteriologically confirmed disease in the area is 313 per 100,000 individuals. Objective: To estimate the rate of recurrent TB attributable to reinfection after successful treatment. Methods: All patients with reported TB in the area between 1993 and 1998 were followed up to 2001 for disease needing retreatment (recurrences). Patients who were multi-drug–resistant or who had treatment failure, were transferred, or died during treatment were excluded. Analysis was restricted to patients for whom DNA fingerprinting of their Mycobacterium tuberculosis isolates was obtained. Reinfection TB was defined as a recurrent TB episode in which the strains of the separate episodes differed by more than four bands. Measurements and Main Results: 612 of 897 (68%) patients had a DNA fingerprint available at enrollment. Median duration of follow-up was 5.2 years. Recurrent TB occurred in 108 of 612 (18%) patients, of whom 61 of 447 (14%) experienced recurrence after successful treatment, and 47 of 165 (28%) experience recurrence after default. Of the 108 patients with recurrent TB, 68 (63%) had a DNA fingerprint in the second episode. Among these patients, 24 of 31 (77%) recurrences after successful treatment and 4 of 37 (11%) recurrences after default were attributable to reinfection. The reinfection disease rate after successful treatment was estimated at 2.2 per 100 person-years. Conclusions: The age-adjusted incidence rate of TB attributable to reinfection after successful treatment was four times that of new TB. People who had TB once are at a strongly increased risk of developing TB when reinfected.

Key Words: incidence • molecular epidemiology • Mycobacterium tuberculosis • recurrence • survival analysis




This article has been cited by other articles:


Home page
Am. J. Respir. Crit. Care Med.Home page
T. Cohen, C. Colijn, A. Wright, M. Zignol, A. Pym, and M. Murray
Challenges in Estimating the Total Burden of Drug-resistant Tuberculosis
Am. J. Respir. Crit. Care Med., June 15, 2008; 177(12): 1302 - 1306.
[Abstract] [Full Text] [PDF]


Home page
BMJHome page
H. S Cox, M. Morrow, and P. W Deutschmann
Long term efficacy of DOTS regimens for tuberculosis: systematic review
BMJ, March 1, 2008; 336(7642): 484 - 487.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
J. Cacho, A. Perez Meixeira, I. Cano, T. Soria, A. Ramos Martos, M. Sanchez Concheiro, S. Samper, P. Gavin, and C. Martin
Recurrent tuberculosis from 1992 to 2004 in a metropolitan area
Eur. Respir. J., August 1, 2007; 30(2): 333 - 337.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
R Nair, K Prabhash, M Sengar, A Bakshi, S Gujral, S Gupta, and P Parikh
The effect of short-term intensive chemotherapy on reactivation of tuberculosis
Ann. Onc., July 1, 2007; 18(7): 1243 - 1245.
[Abstract] [Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
G. Tino
Clinical Year in Review IV: Interstitial Lung Disease, Cystic Fibrosis, Pulmonary Infections, and Mycobacterial Disease
Proceedings of the ATS, November 1, 2006; 3(8): 650 - 653.
[Full Text] [PDF]


Home page
Clin. Microbiol. Rev.Home page
B. Mathema, N. E. Kurepina, P. J. Bifani, and B. N. Kreiswirth
Molecular Epidemiology of Tuberculosis: Current Insights
Clin. Microbiol. Rev., October 1, 2006; 19(4): 658 - 685.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
T. Cohen, M. Lipsitch, R. P. Walensky, and M. Murray
Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations
PNAS, May 2, 2006; 103(18): 7042 - 7047.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
W. W. Yew and C. C. Leung
Update in tuberculosis 2005.
Am. J. Respir. Crit. Care Med., March 1, 2006; 173(5): 491 - 498.
[Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
S. Verver, R. M. Warren, N. Beyers, G. D. van der Spuy, P. D. van Helden, M. W. Borgdorff, D. A. Enarson, and M. A. Behr

Am. J. Respir. Crit. Care Med., January 1, 2006; 173(1): 134 - 135.
[Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
C. F. von Reyn and C. R. Horsburgh
Reinfection with Mycobacterium tuberculosis
Am. J. Respir. Crit. Care Med., January 1, 2006; 173(1): 133a - 134.
[Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
M. A. Behr
Polyclonal Tuberculosis and the Emergence of Drug Resistance
Am. J. Respir. Crit. Care Med., September 1, 2005; 172(5): 521 - 522.
[Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
A. van Rie, T. C. Victor, M. Richardson, R. Johnson, G. D. van der Spuy, E. J. Murray, N. Beyers, N. C. G. van Pittius, P. D. van Helden, and R. M. Warren
Reinfection and Mixed Infection Cause Changing Mycobacterium tuberculosis Drug-Resistance Patterns
Am. J. Respir. Crit. Care Med., September 1, 2005; 172(5): 636 - 642.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
W. W. Yew and C. C. Leung
Are Some People Not Safer after Successful Treatment of Tuberculosis?
Am. J. Respir. Crit. Care Med., June 15, 2005; 171(12): 1324 - 1325.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2005 American Thoracic Society
  ATS Sleep Tracings Quiz